New triple therapy aims to boost remission in elderly AML patients
NCT ID NCT07469046
First seen Mar 27, 2026 · Last updated May 06, 2026 · Updated 5 times
Summary
This phase 3 trial tests whether adding homoharringtonine to the standard two-drug regimen (venetoclax and azacitidine) improves remission rates in adults aged 60-75 with newly diagnosed acute myeloid leukemia (AML). About 308 participants will be randomly assigned to receive either the two-drug or three-drug combination. The study is open-label, meaning both doctors and patients know which treatment is given, but an independent committee will review the results to reduce bias.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, 200080, China
Contact
Conditions
Explore the condition pages connected to this study.